Impact of high-risk classification by FISH: An Eastern Cooperative Oncology Group (ECOG) study E4A03

Lenalidomide with dexamethasone is a standard induction treatment regimen for newly diagnosed myeloma (although a Federal Drug Administration indication is still absent). In the context of the Phase 3 clinical trial E4A03 (lenalidomide plus dexamethasone in low or high doses), we queried whether a f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jacobus, S. J., Kumar, S., Uno, H., Van Wier, S. A., Ahmann, G. J., Henderson, K. J., Callander, N. S., Williams, M. E., Siegel, D. S., Greipp, P. R., Rajkumar, S. V., Fonseca, R.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3192237/
https://ncbi.nlm.nih.gov/pubmed/21902684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08849.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars